Donavon J. McConn - Concepedia

Author

Donavon J. McConn

GlaxoSmithKline (United States)

Also Known As

Donavon J McConn, Donavon J. McConn, Donavon J. Mcconn, Donavon McConn, Tadashi Hashimoto

Publications

607

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)Research Triangle Park Foundation University of Washington Theravance Biopharma (United States)St. Jude Children's Research Hospital

About

Donavon J. McConn is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	162
2	Natural Sciences	1	1	85
3	Biochemistry	1	1	85
4	Cell Biology	1	1	17
5	Cellular Physiology	1	1	17

Donavon J. McConn

Publications

551

Citations

H-Index

Page 1

	Year	Citations
EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM Weili Huang, Yvonne S. Lin, Donavon J. McConn, Drug Metabolism and Disposition	2004	175
Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Donavon J. McConn, Yvonne S. Lin, Kyle E. Allen, PubMed Cytochromes P450 3A4PharmacotherapyPhysiologically-based Pharmacokinetic ModelingPharmaceutical ChemistryMolecular Pharmacology	2004	85
DIFFERENCES IN THE INHIBITION OF CYTOCHROMES P450 3A4 AND 3A5 BY METABOLITE-INHIBITOR COMPLEX-FORMING DRUGS Donavon J. McConn, Yvonne S. Lin, Kyle E. Allen, Drug Metabolism and Disposition	2004	85
An in Vitro Mechanistic Study to Elucidate the Desipramine/Bupropion Clinical Drug-Drug Interaction Melinda J. Reese, Robert M. Wurm, Keith T. Muir, Drug Metabolism and Disposition	2008	82
Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia H Reichard, Hans H. Schiffer, Holger Monenschein, Journal of Medicinal Chemistry	2021	35
Dose‐Related Reduction in Bupropion Plasma Concentrations by Ritonavir Joohyun Park, Marika Vousden, Claire Brittain, The Journal of Clinical Pharmacology Drug InteractionsDosage AdjustmentRepeat Oral DosesPharmacological StudyPharmacology	2010	34
2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV Curt D. Haffner, Darryl McDougald, Steven M. Reister, Bioorganic & Medicinal Chemistry Letters Medicinal Chemistry2-Cyano-4-fluoro-1-thiovalylpyrrolidine AnaloguesMedicinePharmacotherapyAnti-cancer Agent	2005	26
Lysosomes Contribute to Anomalous Pharmacokinetic Behavior of Melanocortin-4 Receptor Agonists Yuping Gong, Zhiyang Zhao, Donavon J. McConn, Pharmaceutical Research Melanocortin-4 Receptor AgonistsDrug TargetSignal TransductionG Protein-coupled ReceptorMedicine	2007	17
Discovery of TD-0212, an Orally Active Dual Pharmacology AT<sub>1</sub> Antagonist and Neprilysin Inhibitor (ARNI) R. Murray McKinnell, Paul R. Fatheree, Seok Ki Choi, ACS Medicinal Chemistry Letters	2018	12

Page 1